Analysts Set LifeStance Health Group, Inc. (NASDAQ:LFST) Price Target at $12.12

LifeStance Health Group, Inc. (NASDAQ:LFST) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $12.1250.

A number of equities analysts have commented on LFST shares. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. BTIG Research boosted their price target on LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. increased their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. The Goldman Sachs Group began coverage on LifeStance Health Group in a research note on Friday, June 5th. They issued a “neutral” rating and a $9.00 price objective on the stock. Finally, KeyCorp increased their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $12.36 on Friday. The firm has a market capitalization of $4.79 billion, a PE ratio of 95.08 and a beta of 1.14. The stock’s fifty day moving average is $10.58 and its 200 day moving average is $8.30. LifeStance Health Group has a fifty-two week low of $4.77 and a fifty-two week high of $12.76. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. LifeStance Health Group’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.01) earnings per share. On average, sell-side analysts anticipate that LifeStance Health Group will post 0.16 earnings per share for the current year.

Insider Transactions at LifeStance Health Group

In related news, CTO Vukasin Paunovich sold 44,394 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at $2,684,789.10. This represents a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Lisa K. Miller sold 47,912 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the transaction, the chief operating officer owned 281,289 shares in the company, valued at approximately $3,051,985.65. The trade was a 14.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 14,629,850 shares of company stock valued at $154,952,012. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds have recently modified their holdings of the business. Larson Financial Group LLC raised its position in shares of LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the last quarter. KBC Group NV acquired a new stake in LifeStance Health Group in the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC grew its position in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock worth $44,000 after purchasing an additional 5,404 shares during the last quarter. PNC Financial Services Group Inc. grew its position in LifeStance Health Group by 615.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after purchasing an additional 7,987 shares during the last quarter. Finally, Assetmark Inc. increased its stake in LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after purchasing an additional 1,367 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.